An ongoing dialogue on HIV/AIDS, infectious diseases,
3 Responses to “Antiretroviral Rounds: Immediate ART After an OI — Are We There Yet?”
Paul E. Sax, MD
Associate Editor
NEJM Clinician
Biography | Disclosures & Summaries
Learn more about HIV and ID Observations.
FROM NEJM — Recent Infectious Disease Articles- The Best of Both Worlds — Using Clinical Trial and Observational Data to Evaluate Vaccine Protection July 18, 2026Well-designed observational studies are critical to advancing understanding of the effects of vaccines. But they are often dismissed as lacking the methodologic rigor necessary to inform policymaking.
- Neurocysticercosis July 18, 2026A 52-year-old woman presented with a 4-month history of headache and visual hallucinations. MRI of the brain showed cystic lesions containing bright nodules.
- National Elimination of Hepatitis C — The Case for Starting in Prisons and Jails July 18, 2026The United States could take meaningful steps toward eliminating hepatitis C by broadly testing and treating people who are involved in the criminal legal system.
- Case 20-2026: A 38-Year-Old Man with Abdominal Pain July 16, 2026A 38-year-old man was evaluated at the hospital because of postprandial abdominal pain. Six weeks earlier, a diarrheal illness had developed while he was working in Madagascar. A diagnosis was made.
- Bundibugyo Virus Disease in 2026 — Clinical and Public Health Responses July 16, 2026This review summarizes the current state of the 2026 filovirus disease outbreak in the Democratic Republic of Congo, as well as the principles and approaches that are informing the response.
- The Best of Both Worlds — Using Clinical Trial and Observational Data to Evaluate Vaccine Protection July 18, 2026
I never start with Atripla per se, but split it as Truvada plus Sustiva for the first month or so, in case pt doesn’t tolerate efavirenz side effects.
Practicing in New York city I see many patients similar to the case that was described.
The immediate versus delayed initiation of ART in my view should depend on CD4 count. I may start ART in a patient with CD4>100 earlier than the one with CD4<50.
The lower the CD4 count the more chance of other hidden OIs . These infections should be screened first before initiating ART . This can be done safely in 2-4 weeks with special screening for significant OIs like CMV, crypt, etc….
This lag in initiation of ART and the medication/s needed for treatment of thepresenting OI while screening for other OIs also safeguard us against complexity of overlapping side effects by introducing the medications stepwise. Patient tolerance improves and compliance improves as well.
Excellent site, keep up the good work